Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ProStrakan pays GTx $21.7mm for US rights to Fareston

Executive Summary

GTx Inc. (cancer and cancer supportive care therapeutics) has licensed ProStrakan Group PLC, the specialty pharma division of Kyowa Hakko Kirin Co. Ltd., exclusive US rights to the breast cancer drug Fareston (toremifene, 60mg tablets). ProStrakan paid $21.7mm in cash ($19mm net of related expenses).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies